-
APhA announces 25 companies participating in Project Impact: Diabetes
WASHINGTON — The American Pharmacists Association Foundation announced Monday the selection of 25 companies, community health departments and other organizations — collectively known as “communities” — that will take part in the foundation’s initiative to improve care for people disproportionately affected by diabetes across the United States.
-
Actos cuts Type 2 diabetes risk among majority of patients, study finds
SAN ANTONIO — A drug for Type 2 diabetes made by Takeda Pharmaceutical taken in the morning prevented the disease from developing in nearly three-quarters of patients who were at risk, according to a new study in the New England Journal of Medicine.
Researchers enrolled 602 patients through the University of Texas Health Science Center San Antonio and seven other centers and administered Actos (pioglitazone) to them, finding that it prevented Type 2 diabetes in 72% of those whose obesity, ethnicity and other factors put them at risk for the disease.